{"id":"NCT01297920","sponsor":"Alcon Research","briefTitle":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","officialTitle":"A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2011-02-17","resultsPosted":"2013-07-04","lastUpdate":"2013-07-04"},"enrollment":1062,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Brinzolamide ophthalmic suspension, 1%","otherNames":[]},{"type":"DRUG","name":"Brimonidine tartrate ophthalmic solution, 0.2%","otherNames":[]}],"arms":[{"label":"Brinz/Brim","type":"EXPERIMENTAL"},{"label":"Brinzolamide","type":"ACTIVE_COMPARATOR"},{"label":"Brimonidine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle glaucoma and/or ocular hypertension.","primaryOutcome":{"measure":"Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"Brinz/Brim","deltaMin":21.1,"sd":0.3},{"arm":"Brinzolamide","deltaMin":22,"sd":0.29},{"arm":"Brimonidine","deltaMin":23.2,"sd":0.3}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":221},"commonTop":["Dysgeusia","Conjunctivitis","Vision blurred","Eye irritation","Eye allergy"]}}